• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Experimental drug for itchy skin in atopic dermatitis patients


In this Medical News Minute, Dr. Lazzara discusses the findings of a recent study that examined the dosage of an experimental drug for the treatment of itchy skin in people with atopic dermatitis.

Published in the Journal of Allergy and Clinical Immunology, a study looking at the dosage of an experimental drug nemolizumab for the treatment of itchy skin in people with atopic dermatitis eczema and severe pruritus.

Researchers evaluated a new dosing strategy for the drug over a 24 week randomized double blind study that compared varying doses administered by injection versus placebo with concomitant use of topical corticosteroids.

The Findings: The drug lessened severity of itchiness and size of affected areas. Overall, nemolizumab made rapid and sustained improvement in patients with maximal efficacy observed at doses of 30 milligrams

Given that the dosing strategy for this drug is still in an experimental phase, how will you talk to your patients about trying it – or will you?

Related Videos
Video 2 - "Atopic Dermatitis and Contact Dermatitis: Navigating Intersecting Pathways and Optimal Management Strategies"
Video 1 - "Decoding Atypical Atopic Dermatitis: Unraveling Complex Cases and Advanced Diagnostic Strategies"
Elizabeth Kiracofe, MD, an expert on atopic dermatitis
© 2024 MJH Life Sciences

All rights reserved.